4Kunos CA, Sill MW, Buekers TE, et al. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group [ J ]. Gynecologic oncology, 2011,120 ( 2 ) : 224 - 228.
6Subbarayan PR, Lee K, Ardalan B. Arsenic trioxide suppresses thymi- dylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU [ J ]. Anticancer research, 2010, 30(4) :1157 - 1162.
8Asano T, Tsutsuda-asano A, Fukunaga Y. Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of gamma-glu- tamylcysteine synthetase via promoter activity in doxorubicin-resistanct leukemia cells [ J]. Cancer Chemother Pharmacol, 2009,64(4) :715 -721.
1Akutsu Y, Shuto K, Kono T, et al. A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma. Hepatogastroenterology. 2012;59(119): 2095-2098.
2Fencl P, Belohlavek O, Harustiak T, et al. The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma. Nucl Med Commun. 2012; 33(11) 1188-1194.
3Ji Y, Zheng MF, Ye SG, et al. Agrocybe aegerita polysaccharide combined with chemotherapy improves tumor necrosis factor-a and interferon-~ levels in rat esophageal carcinoma. Dis Esophagus. 2013;26(8):859- 863.
4Kobayashi N, Nakayama H, Osaka Y, et al. Tumor response after 10w-dose preoperative radiotherapy combined with chemotherapy for squamous cell esophageal carcinoma. Anticancer Res. 2013;33(3):1157-1161.
5Choi N, Park SD, Lynch T, et al. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Int J Radiat Oncol Biol Phys. 2004;60(1):111-122.
6Kim MK, Cho K J, Park SI, et al. Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009; 75(1):115-121.
7Akutsu Y, Kono T, Uesato M, et al. S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. Oncology 2013;84(5):305-310.
8Koo DH, Park SI, Kim YH, et al. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemother Pharmacol. 2012;69(3):655-663.
